WHITE PAPER: Using Artificial Intelligence To Determine Patient Response To Immunotherapy

Key Concepts:

  • While the current diagnostic strategies for PD-L1 checkpoint inhibitors identify some responders well, the majority of patients still need diagnostic approaches that better predict response.
  • PD-L1 IHC remains a valuable tool for predicting patient response, but can be limited by the ability to correctly use the test to interpret the complex underlying biology and response profile.
  • New IHC interpretation methods are capturing this biology and defining better patient selection tests, but the interpretations are complicated and hard for pathologists to implement.

Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.

Recent Posts